Dr. Sherrie Holdman is an associate at Wilson Sonsini Goodrich & Rosati, where she is a member of the patents and innovations practice. She focuses her practice on patent prosecution, portfolio management, and strategic client counseling in the life sciences and biotechnology industries. She has experience in preparing new patent applications, prosecuting U.S. and foreign applications, managing global patent portfolio, and providing patentability opinions in both private practice and as in-house counsel. Sherrie is familiar with both U.S. and Chinese patent law.
Sherrie’s technical experience includes antibodies, anti-cancer agents, biologics, diagnostic markers, gene therapy, gene editing technologies, medical devices, sequencing technologies, small molecule drugs, and stem cell technologies.
Sherrie received her Ph.D. from Baylor College of Medicine, where she studied the molecular mechanism of cancer recurrence and targeted therapy for breast cancer.
Sherrie is practicing virtually in Illinois, where she is licensed.
Dr. Sherrie Holdman is an associate at Wilson Sonsini Goodrich & Rosati, where she is a member of the patents and innovations practice. She focuses her practice on patent prosecution, portfolio management, and strategic client counseling in the life sciences and biotechnology industries. She has experience in preparing new patent applications, prosecuting U.S. and foreign applications, managing global patent portfolio, and providing patentability opinions in both private practice and as in-house counsel. Sherrie is familiar with both U.S. and Chinese patent law.
Sherrie’s technical experience includes antibodies, anti-cancer agents, biologics, diagnostic markers, gene therapy, gene editing technologies, medical devices, sequencing technologies, small molecule drugs, and stem cell technologies.
Sherrie received her Ph.D. from Baylor College of Medicine, where she studied the molecular mechanism of cancer recurrence and targeted therapy for breast cancer.
Sherrie is practicing virtually in Illinois, where she is licensed.
- University of Minnesota Law School, 2020Cum Laude
- Ph.D., Integrative Molecular and Biomedical Sciences, Baylor College of Medicine, 2015
- M.S., Biochemistry and Molecular Biology, Chinese Academy of Sciences, 2010
- B.S., Biotechnological Pharmaceutics, Shenyang Pharmaceutical University, Shenyang, 2007
- Certified Licensing Professional (CLP), Certified Licensing Professionals, Inc.
- Regulatory Affairs Certification, Pharmaceuticals (RAC-Drugs)
- State Bar of Illinois
- State Bar of Massachusetts
- U.S. Patent and Trademark Office
- University of Minnesota Law School, 2020Cum Laude
- Ph.D., Integrative Molecular and Biomedical Sciences, Baylor College of Medicine, 2015
- M.S., Biochemistry and Molecular Biology, Chinese Academy of Sciences, 2010
- B.S., Biotechnological Pharmaceutics, Shenyang Pharmaceutical University, Shenyang, 2007
- Certified Licensing Professional (CLP), Certified Licensing Professionals, Inc.
- Regulatory Affairs Certification, Pharmaceuticals (RAC-Drugs)
- State Bar of Illinois
- State Bar of Massachusetts
- U.S. Patent and Trademark Office
- “Helsinn Healthcare S.A. v. Teva Pharmaceutical USA, Inc.: ‘Sale’ Keeps Its Old Meaning Under the Leahy-Smith America Invents Act,” Minnesota Journal of Law, Science & Technology, 2018
- Co-author, “Oncogenic mTOR Signaling Recruits Myeloid-Derived Suppressor Cells to Promote Tumor Initiation,” 18(6) Nature Cell Biology, 632-44, 2016
- Co-author, “Upregulation of EGFR Signaling is Correlated with Tumor Stroma Remodeling and Tumor Recurrence in FGFR1-driven Breast Cancer,” 17 Breast Cancer Research 141-58, 2015
- Co-author, “Fibroblast Growth Factor Receptor Signaling is Essential for Normal Mammary Gland Development and Stem Cell Function,” 31(1) Stem Cells 178-89, 2013
- “Helsinn Healthcare S.A. v. Teva Pharmaceutical USA, Inc.: ‘Sale’ Keeps Its Old Meaning Under the Leahy-Smith America Invents Act,” Minnesota Journal of Law, Science & Technology, 2018
- Co-author, “Oncogenic mTOR Signaling Recruits Myeloid-Derived Suppressor Cells to Promote Tumor Initiation,” 18(6) Nature Cell Biology, 632-44, 2016
- Co-author, “Upregulation of EGFR Signaling is Correlated with Tumor Stroma Remodeling and Tumor Recurrence in FGFR1-driven Breast Cancer,” 17 Breast Cancer Research 141-58, 2015
- Co-author, “Fibroblast Growth Factor Receptor Signaling is Essential for Normal Mammary Gland Development and Stem Cell Function,” 31(1) Stem Cells 178-89, 2013
- Privacy Policy
- Terms of Use
- Accessibility